PubMed Health⌕ Search

Biomedical subjects

E S Baum

Publications and source records attributed to E S Baum.

28 records · Page 2Linked to original sources
PubMed1981

Pulmonary resection and chemotherapy for metastatic alveolar soft-part sarcoma.

Alveolar soft-part sarcoma (ASPS) is an unusual tumor of soft tissues; it has invariably ended in death from disseminated disease, and the lung has been the most common site of metastasis. We present a patient with ASPS with bilateral pulmonary metastases who achieved a complete response after bilateral thoracotomies with removal of all gross disease and after combination chemotherapy including vincristine, actinomycin D, cyclophosphamide, and doxorubicin. The patient has now been followed for five years since the appearance of the metastases and has been off therapy for the past 34 months. He shows no evidence of disease. We suggest that multimodality therapy is a reasonable approach in patients with ASPS and pulmonary metastases and that such therapy has the potential for improving survival.

Adolescent↗
PubMed1981

Bleomycin-induced pulmonary fibrosis mimicking recurrent metastatic disease in a patient with testicular carcinoma: case report of the CT scan appearance.

Pulmonary fibrosis is a well-recognized complication of bleomycin therapy. Detection of bleomycin-induced pulmonary fibrosis by computed axial tomographic scanning (CT) has not been reported. We report on a patient in whom the development of lesions on chest CT scan following cessation of chemotherapy (including bleomycin) was interpreted as representing recurrent metastatic disease. At bilateral thoracotomy, only pulmonary fibrosis was found. In this patient, the CT scan appearance of bleomycin-induced pulmonary fibrosis mimicked recurrent disease.

Adolescent↗
PubMed1976

Current trends in treatment of childhood rhabdomyosarcoma of lower genitourinary tract.

Treatment of childhood embryonal rhabdomyosarcoma of the lower genitourinary tract is in the process of undergoing drastic changes. Extensive surgery with excision of the lesion and its contiguous structures leaving the patient with significant physical disability is being replaced by biopsy and aggressive combined chemotherapy along with radiation therapy. Although it would appear that survival may be improved by this approach, caution is recommended and extirpation advised should the tumor fail to respond rapidly to chemotherapy.

Biopsy, Needle↗
PubMedDate not supplied

Phase II trail cisplatin in refractory childhood cancer: Children's Cancer Study Group Report.

A total of 114 children with solid tumors refractory to conventional therapy were evaluated for response and/or toxic effects after receiving cisplatin at doses of 3.0-4.5 mg/kg with aggressive hydration and mannitol diuresis every 3 weeks; a minimum of two courses was required for evaluation of response (110 patients). Objective responses were noted in 18 patients: rhabdomyosarcoma (three), Wilm's tumor (three), osteogenic sarcoma (three). Ewing's sarcoma (two), neuroblastoma (one), undifferentiated sarcoma (one), hepatoblastoma (one), ovarian teratoma (one), hepatocellular carcinoma (one), embryonal carcinoma of the mediastinum (one), and thymoma (one). Twenty-six patients had some evidence of renal toxicity. Asymptomatic hearing loss was commonly found when audiometry was performed (eight of 18 patients tested). Eight additional patients had symptomatic hearing problems--tinnitus or hearing loss. Myelosuppression was mild. Hypomagnesemia and/or hypocalcemia were common but only one patient had symptoms. Cisplatin, administered at a dose of 3.0 mg/kg with aggressive hydration and mannitol diuresis, is reasonably well-tolerated. Its role in the therapy for those tumors against which it shows activity remains to be determined.

Adolescent↗